Two drug companies revealed, critically ill COVID-19 patients experienced rapid recovery from respiratory failure after getting treated with RLF-100 (Aviptadil).

The drug was developed through a partnership between two drug companies. 

Relief Therapeutics, a Swiss-based drug development company, and NeuroRx, a molecule pharmaceutical company, both worked together on this drug. 

The US Food and Drug Administration (FDA), granted the Aviptadil an FDA Fast Track Designation, said NeuroRx.

The Aviptadil is now on its phase ⅔ of its clinical trial, as per NeuroRx. 

They are currently treating seventy COVID-19 patients, as per a New York Post report. 

The Aviptadil, according to NeuroRx, is a synthetic form of a natural type of peptide. 

This type of peptide also lacks toxicity and the cost to manufacture is lower. 

Reports Of Fast Recovery

According to the two companies, doctors from the Houston Methodist Hospital first reported a rapid recovery from a patient. 

A 54-year-old man came off his ventilator after 4 days of Aviptadil treatment, the doctors said. 

The Aviptadil also stopped the reproduction of the SARS virus in human lung cells. 

Race To COVID-19 Cure

As of July 30th, there are already 166 vaccines being developed by different countries all over the world, said the WHO. 

26 of them are already candidates for clinical evaluation, while the others are candidates for preclinical evaluation. 

Also, 6 among the 26 are farther ahead than the others and are in phase 3 of their clinical stage. 

The 6 includes these companies:

  1. Sinovac
  2. Oxford/AstraZeneca
  3. Wuhan Institute of Biological Products/Sinopharm
  4. Beijing Institute of Biological Products/Sinopharm
  5. Moderna/NIAID, and
  6. BioNtech/Fosun Pharma/Pfizer

Developers who are in Phase 3 are already checking their vaccines’ efficacy. 

This will also determine if the virus can protect people.

According to the New York Times, the vaccine should protect at least, 50% of the vaccinated people to prove its effectiveness. 

LEAVE A REPLY

Please enter your comment!
Please enter your name here